MOTS-c Dosage: What Community Protocols Report
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← MOTS-c encyclopedia entry · See also: BPC-157 dosage · Regulatory tracker
MOTS-c is investigational and not FDA approved, and its evidence base is overwhelmingly preclinical (cell and animal studies). There is no label and no validated human dose. The figure below is a community report, documented for education — not instructions for use. An unapproved injectable carries unknowns of identity, purity, and sterility.
The short version
MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within the mitochondrial genome rather than the cell nucleus, which is part of why it is scientifically interesting. In animal studies it acts as a metabolic regulator, activating the cellular energy sensor AMPK and producing effects that have led researchers to describe it as an "exercise mimetic." The honest summary for dosing purposes is that the compelling biology is almost entirely in mice and cells, so any human "dose" is an extrapolation.
What community protocols report
Longevity and biohacker protocols most commonly report the following. It is descriptive, not prescriptive.
| Parameter | Commonly reported |
|---|---|
| Amount | ~5–10 mg weekly |
| Frequency | Weekly (sometimes split) |
| Route | Subcutaneous |
| Pattern | Time-limited cycles |
The weekly cadence is convention rather than something established by human pharmacokinetic data, which for MOTS-c is sparse. Because the animal work often involves repeated dosing relative to body weight, naive translation to a fixed human milligram dose is exactly the kind of extrapolation to be skeptical of.
Where MOTS-c stands legally
MOTS-c was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 after nominations were withdrawn — which is not approval. It is one of the compounds scheduled for PCAC review on July 23, 2026, the earliest of the current review cycle. Until that concludes it remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
MOTS-c is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before a dose can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw. As always, a calculator can do the arithmetic but cannot verify that the vial contains what the label claims, or that it is pure and sterile.
Frequently asked questions
Is MOTS-c really an "exercise mimetic"?
That description comes from animal studies showing improved metabolic and exercise-capacity measures. Whether those effects translate to humans at any dose is unproven — it is a research hypothesis, not an established result.
Why weekly dosing?
It is a community convention; robust human pharmacokinetic data that would justify a specific interval are not available.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural; MOTS-c awaits its July 2026 PCAC review and is not an approved medicine.
Sources
- Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21:443–454.
- Reynolds JC, et al. MOTS-c and exercise/metabolic regulation.
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.
Medical disclaimer: Education only, not medical advice. MOTS-c is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.